Milprazon 2.5mg/25mg for Small Dogs and Puppies

Description

Milprazon 2.5mg/25mg for Small Dogs and Puppies delivers dual-active anthelmintic therapy through a combination of milbemycin oxime and praziquantel in a single oral tablet. The formulation targets both nematode and cestode infections concurrently, addressing mixed parasitic burdens with a single monthly dose. Each tablet is scored to allow division into equal halves, enabling precise dosing for puppies at the lower boundary of this weight band (0.5 kg to 1 kg). Palatability studies indicate voluntary acceptance in over 80% of animals studied.

Recommended for: Small dogs and puppies weighing 0.5 kg to 5 kg, from 2 weeks of age.

Indication/Coverage

For dogs suffering from, or at risk from, mixed parasitic infections, the labeled indications for Milprazon 2.5 mg/25 mg cover the following:

• Dipylidium caninum (tapeworm): Treatment of adult cestode infection; concurrent flea and lice control is recommended to interrupt the parasite’s lifecycle and prevent re-infestation.
• Taenia spp. (tapeworm): Treatment of adult cestode infection in the gastrointestinal tract.
• Echinococcus spp. (hydatid tapeworm): Treatment of adult cestode infection; this genus is zoonotic and notifiable to WOAH, requiring local regulatory guidance for follow-up protocols.
• Mesocestoides spp. (tapeworm): Treatment of adult cestode infection.
• Ancylostoma caninum (hookworm): Treatment of adult nematode infection causing intestinal blood loss, particularly in young or debilitated dogs.
• Toxocara canis (roundworm): Treatment of adult nematode infection; zoonotic potential warrants attention in households with children.
• Toxascaris leonina (roundworm): Treatment of adult nematode infection of the gastrointestinal tract.
• Trichuris vulpis (whipworm): Treatment of adult nematode infection causing large intestinal inflammation.
• Crenosoma vulpis (fox lungworm): Reduction of infection burden; does not achieve complete elimination at a single standard dose.
• Angiostrongylus vasorum (French heartworm): Reduction of immature adult (L5) and adult parasite burden. Milbemycin oxime should be given four times at weekly intervals. Use Milprazon for the first weekly dose, then use a milbemycin oxime-only product for the next 3 weekly doses if tapeworm treatment is also needed. In endemic areas where concurrent tapeworm treatment is required, monthly dosing with Milprazon reduces ongoing parasite burden.
• Thelazia callipaeda (eyeworm): Treatment requires two milbemycin oxime administrations seven days apart. Where concomitant tapeworm treatment is indicated, Milprazon can replace the monovalent milbemycin oxime product for this schedule.
• Dirofilaria immitis (heartworm, prevention only): Monthly dosing prevents establishment of larval heartworm when concomitant tapeworm treatment is indicated; this product is not a stand-alone heartworm preventive and is not labeled for adulticidal therapy.

Key Benefits

Milprazon 2.5 mg/25 mg addresses the clinical requirements of small-breed and puppy deworming through the following pharmacological properties:

• Minimum age suitability: Labeled for puppies from 2 weeks of age weighing at least 0.5 kg, covering the earliest period of life when nematode and cestode exposure is clinically significant.
• Dual drug class coverage: Milbemycin oxime targets nematodes and heartworm larvae; praziquantel targets cestodes and trematodes. A single tablet treats mixed infections without requiring separate products for each parasite class.
• Nematode mechanism: Milbemycin oxime increases membrane permeability to chloride ions via glutamate-gated chloride channels, inducing hyperpolarisation and flaccid paralysis in nematodes and insect larvae at the neuromuscular junction.
• Cestode mechanism: Praziquantel alters calcium membrane permeability in cestode tegument, triggering rapid muscular tetany, tegumental disintegration, and expulsion from the gastrointestinal tract.
• Palatability rate: Voluntary acceptance was recorded in over 80% of animals studied, reducing the clinical need for forced oral administration in most patients.
• Tablet division for small patients: The scored tablet divides into equal halves, permitting accurate dosing for puppies in the 0.5 kg to 1 kg range without dose estimation or compounding.
• Heartworm prevention when cestode treatment is concurrent: In heartworm-risk areas where tapeworm treatment is also indicated, Milprazon replaces the single-ingredient milbemycin product, consolidating two parasite control objectives into one tablet.
• Safe during reproduction: The product is labeled for use during pregnancy and lactation, and in breeding animals, based on available reproductive safety data from the manufacturer KRKA.

Caution

Hazards to Humans

Accidental ingestion of a tablet by a child may cause harm; store and administer this product out of sight and reach of children. If a child ingests one or more tablets, seek medical attention immediately and present the package leaflet to the treating physician. Wash hands after handling the product or administering it to an animal.

Hazards to Domestic Animals

Do not administer to puppies under 2 weeks of age or weighing less than 0.5 kg; dosing below this threshold has not been studied. Dogs with severely compromised kidney or liver function, or those in a debilitated state, should be assessed by a veterinarian before treatment commences, as no safety data exist for these animals. The macrocyclic lactone class, to which milbemycin oxime belongs, carries a reduced margin of safety in Collie and related MDR1-affected breeds; the recommended dose should be observed precisely in these animals. In heartworm-endemic areas, or for dogs with recent travel history to such regions, a veterinary consultation is advised before use to rule out existing adult heartworm infection, since the product is not labeled for adulticidal therapy. Concurrent use with other macrocyclic lactones requires caution in the absence of full interaction data.

Possible Side Effects

Monitor your dog after administration for any change in behavior or physical condition, particularly following the first dose.

The following adverse reactions have been reported at very rare frequency (fewer than 1 in 10,000 animals treated):

• Hypersensitivity reactions: Dogs carrying a high burden of circulating microfilariae may develop pale mucous membranes, vomiting, trembling, laboured breathing, or excessive salivation following administration; these reactions result from protein release during microfilariae death, not from direct drug toxicity.
• Neurological signs: Muscle tremors and ataxia have been reported at very rare frequency; Collie and related MDR1-affected breeds carry a narrower margin of safety with milbemycin oxime and require strict adherence to the labeled dose.
• Gastrointestinal signs: Emesis, diarrhoea, anorexia, and drooling have been recorded at very rare frequency following oral administration.
• Systemic signs: Lethargy has been documented at very rare frequency.

If any of these signs appear following administration, consult a veterinarian before giving the next scheduled dose.